|
Decision 839/2024 |
||
|---|---|---|
| File (PDF) | Decision 839/2024 | |
| Date of Issuance of Decision | 05/01/2024 | |
| Issue Number of Government Gazette | 2029/B΄/28.04.2025 | |
| Relevant Market |
Market for the wholesale, imports, exports and distribution of drugs and pharmaceutical products, pharmaceutical substances and parapharmaceutical products. |
|
| Subject of the Decision |
Clearance decision on the notified concentration, pursuant to Articles 5-10 of Law 3959/2011, concerning the acquisition of sole control by the company under the name “PROFARM S.A.” over the companies a) “PHARMA GROUP MESSINIAS S.A.”, b) “PHARMA GROUP ACHAIAS S.A.” and c) “PHARMA GROUP ARGOLIDAS S.A.”, within the meaning of article 5(2)(b) of Law 3959/2011. |
|
| Legal Framework |
Articles 5-10 of Law 3959/2011. |
|
|
Operative part of the Decision |
The Hellenic Competition Commission, in Chamber sitting, unanimously approved, under article 8(3) of Law 3959/2011, the notified concentration under ref. no. 9008/17.11.2023 concerning the acquisition of sole control by the company under the name “PROFARM S.A.” over the companies a) “PHARMA GROUP MESSINIAS S.A.”, b) “PHARMA GROUP ACHAIAS S.A.” and c) “PHARMA GROUP ARGOLIDAS S.A.”, as, although falling within the scope of article 6(1) of Law 3959/2011, it does not raise serious concerns as to its compatibility with competition rules in the markets concerned. |
|
| Company(ies) concerned |
|
|
| Summary of Decision | The proposed transaction does not lead to any horizontal overlaps or vertical relationships between the parties concerned. Therefore, it does not raise serious concerns as to its compatibility with competition rules in the individual markets concerned. | |
| Judicial Means | - | |
| Decisions by the Court of Appeal of Athens (Administrative Division) | - | |
